FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048200020> ?p ?o ?g. }

• W2048200020 endingPage "6" @default.
• W2048200020 startingPage "S1" @default.
• W2048200020 abstract "Abstract Background: Resistance to hormonal therapy may be associated with activation of the PI3K/AKT pathway. Preclinically, everolimus (RAD), an oral inhibitor of mTOR, has been shown to reverse resistance to tamoxifen (TAM). In a prior randomized phase II trial in estrogen-receptor positive operable breast cancer pts, RAD significantly increased neoadjuvant AI (letrozole) efficacy when given in combination. The objective of this randomized phase II study was to estimate the efficacy of the RAD+TAM combination in AI pretreated hormone-receptor positive/HER2 negative MBC pts based on the assumption that prior exposure to an AI might potentially enrich the proportion of pts whose tumor may be driven by an activation of the PI3K/AKT/mTOR pathway. Methods: Eligible patients were stratified by time to progression after prior AI treatment and randomized 1:1 to receive either TAM (20mg/day) alone or RAD+TAM (RAD: 10 mg/d; TAM: 20mg/d). The primary objective was to estimate clinical benefit rate (CB) defined as the absence of progression at 6 months in the RAD+TAM arm. Using a Simon two-stage Minimax design, with alpha=5% and power=90%, considering a gain in CB of 20% as the minimum needed to warrant further study for the combination and assuming a CB of 50% in the TAM arm, 53 evaluable patients were needed in both arms. Secondary endpoints included safety and time to progression (TTP). Results: In total, 111 pts (TAM: 57, RAD+TAM: 54) were randomized. Baseline characteristics were well balanced between the two treatment arms; median age was 64 years (range, 41-86); most pts were PS 0 (55 pts, 51%) or PS 1 (46 pts, 43%) Prior AI treatment had been given to 34 pts (31%) in the adjuvant setting; to 67 pts (60%) in the metastatic setting and 10 pts (9%) in both the adjuvant and metastatic setting. This population was poorly hormone sensitive as all but 10 pts (9%) had progressed either during AI or within 6 months after adjuvant AI. Furthermore, 57 pts (51%) and 28 pts (25%) had received prior chemotherapy in the adjuvant and/or metastatic setting, respectively. Efficacy: In an intent-to-treat analysis with a median follow-up of 13 months, CB was 42.1% (95% CI, 29.1-55.9) in the TAM arm and 61.1% (95% CI, 46.9-74.1) in the RAD+TAM arm. Median TTP was 4.5 months (95% CI, 3.7-8.7) with TAM and 8.5 months (95% CI, 6.01-13.9) with RAD+TAM (log-rank test: p=0.008, exploratory analysis). At the time of analysis, 17 pts had died in the TAM arm and 5 patients had died in the RAD+TAM arm (there was no toxic death). Safety: Safety data showed that toxicity was manageable in both groups. RAD had to be decreased to 5 mg/day for 15 pts (28%); 3 and 2 pts had to stop the treatment due to toxicities in the TAM and RAD+TAM arms respectively. Severe adverse events (G3-4) &gt;10% were stomatitis (0/11%, TAM/RAD+TAM) and pain (19%/7%). Conclusions: RAD combined with tamoxifen provides significant improvement in the 6 months clinical benefit rate compared to tamoxifen alone. Based on these promising results, this combination warrants further study in hormone-receptor positive/HER2 negative MBC after progression on AI. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr S1-6." @default.
• W2048200020 created "2016-06-24" @default.
• W2048200020 creator A5001484228 @default.
• W2048200020 creator A5004676554 @default.
• W2048200020 creator A5031166559 @default.
• W2048200020 creator A5035139653 @default.
• W2048200020 creator A5038384830 @default.
• W2048200020 creator A5046350905 @default.
• W2048200020 creator A5053950718 @default.
• W2048200020 creator A5059319045 @default.
• W2048200020 creator A5061202255 @default.
• W2048200020 creator A5075436616 @default.
• W2048200020 creator A5076536874 @default.
• W2048200020 creator A5077714048 @default.
• W2048200020 creator A5083194487 @default.
• W2048200020 creator A5090608495 @default.
• W2048200020 date "2010-12-01" @default.
• W2048200020 modified "2023-10-01" @default.
• W2048200020 title "Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI)." @default.
• W2048200020 doi "https://doi.org/10.1158/0008-5472.sabcs10-s1-6" @default.
• W2048200020 hasPublicationYear "2010" @default.
• W2048200020 type Work @default.
• W2048200020 sameAs 2048200020 @default.
• W2048200020 citedByCount "32" @default.
• W2048200020 countsByYear W20482000202012 @default.
• W2048200020 countsByYear W20482000202013 @default.
• W2048200020 countsByYear W20482000202015 @default.
• W2048200020 countsByYear W20482000202019 @default.
• W2048200020 countsByYear W20482000202021 @default.
• W2048200020 countsByYear W20482000202022 @default.
• W2048200020 crossrefType "journal-article" @default.
• W2048200020 hasAuthorship W2048200020A5001484228 @default.
• W2048200020 hasAuthorship W2048200020A5004676554 @default.
• W2048200020 hasAuthorship W2048200020A5031166559 @default.
• W2048200020 hasAuthorship W2048200020A5035139653 @default.
• W2048200020 hasAuthorship W2048200020A5038384830 @default.
• W2048200020 hasAuthorship W2048200020A5046350905 @default.
• W2048200020 hasAuthorship W2048200020A5053950718 @default.
• W2048200020 hasAuthorship W2048200020A5059319045 @default.
• W2048200020 hasAuthorship W2048200020A5061202255 @default.
• W2048200020 hasAuthorship W2048200020A5075436616 @default.
• W2048200020 hasAuthorship W2048200020A5076536874 @default.
• W2048200020 hasAuthorship W2048200020A5077714048 @default.
• W2048200020 hasAuthorship W2048200020A5083194487 @default.
• W2048200020 hasAuthorship W2048200020A5090608495 @default.
• W2048200020 hasConcept C121608353 @default.
• W2048200020 hasConcept C126322002 @default.
• W2048200020 hasConcept C143998085 @default.
• W2048200020 hasConcept C168563851 @default.
• W2048200020 hasConcept C2775930923 @default.
• W2048200020 hasConcept C2777176818 @default.
• W2048200020 hasConcept C2778812593 @default.
• W2048200020 hasConcept C2779699572 @default.
• W2048200020 hasConcept C530470458 @default.
• W2048200020 hasConcept C71924100 @default.
• W2048200020 hasConcept C84606932 @default.
• W2048200020 hasConceptScore W2048200020C121608353 @default.
• W2048200020 hasConceptScore W2048200020C126322002 @default.
• W2048200020 hasConceptScore W2048200020C143998085 @default.
• W2048200020 hasConceptScore W2048200020C168563851 @default.
• W2048200020 hasConceptScore W2048200020C2775930923 @default.
• W2048200020 hasConceptScore W2048200020C2777176818 @default.
• W2048200020 hasConceptScore W2048200020C2778812593 @default.
• W2048200020 hasConceptScore W2048200020C2779699572 @default.
• W2048200020 hasConceptScore W2048200020C530470458 @default.
• W2048200020 hasConceptScore W2048200020C71924100 @default.
• W2048200020 hasConceptScore W2048200020C84606932 @default.
• W2048200020 hasIssue "24_Supplement" @default.
• W2048200020 hasLocation W20482000201 @default.
• W2048200020 hasOpenAccess W2048200020 @default.
• W2048200020 hasPrimaryLocation W20482000201 @default.
• W2048200020 hasRelatedWork W1040971774 @default.
• W2048200020 hasRelatedWork W1491737910 @default.
• W2048200020 hasRelatedWork W1971410221 @default.
• W2048200020 hasRelatedWork W1976047942 @default.
• W2048200020 hasRelatedWork W1997495011 @default.
• W2048200020 hasRelatedWork W2065280895 @default.
• W2048200020 hasRelatedWork W2072761001 @default.
• W2048200020 hasRelatedWork W2073317050 @default.
• W2048200020 hasRelatedWork W2090744251 @default.
• W2048200020 hasRelatedWork W2103643613 @default.
• W2048200020 hasVolume "70" @default.
• W2048200020 isParatext "false" @default.
• W2048200020 isRetracted "false" @default.
• W2048200020 magId "2048200020" @default.
• W2048200020 workType "article" @default.